Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy

Fresenius is shoring up its near-term US growth prospects by acquiring generics firm Akorn, as well boosting its future outlook by entering the biosimilars space via a deal with Merck KgaA.

German healthcare company Fresenius SE & Co. KGAA has accelerated the pace of its M&A activity since promoting its CFO Stephan Sturm to the CEO role in July last year.

Following its acquisition of Spanish private hospital group Quironsalud for $6.1bn in 2016, it has confirmed it is buying US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip